Markets

Insider Trading

Hedge Funds

Retirement

Opinion

5 Best Healthcare Stocks Under $50

In this article, we will be taking a look at the 5 best healthcare stocks under $50. To read our detailed analysis of the healthcare sector, you can go directly to see the 11 Best Healthcare Stocks Under $50.

5. Catalent, Inc. (NYSE:CTLT)

Number of Hedge Fund Holders: 42

Share Price as of July 21: $47.88

Catalent, Inc. (NYSE:CTLT) is a pharmaceutical company based in Somerset, New Jersey. It provides solutions for drugs, protein-based biologics, and more.

On June 30, Sean Dodge at RBC Capital reiterated an Outperform rating and $49 price target on Catalent, Inc. (NYSE:CTLT) shares.

Catalent, Inc. (NYSE:CTLT) had 42 hedge funds long its stock in the first quarter, with a total stake value of $1.2 billion.

Aristotle Capital Boston, LLC mentioned Catalent, Inc. (NYSE:CTLT) in its first-quarter 2023 investor letter:

Catalent, Inc. (NYSE:CTLT), a pharmaceutical contract development and manufacturing organization, appreciated amid positive momentum within the company’s Biologics segment, a renewed focus on improving efficiencies, and rumblings that the company may be acquired. We maintain a position, as we believe the long-term value creation opportunity for the company remains intact, driven by favorable outsourcing trends and the company’s competitive position in biologics, particularly within the company’s cell and gene therapy sub-segments.”

Follow Catalent Inc. (NYSE:CTLT)

4. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Number of Hedge Fund Holders: 44

Share Price as of July 21: $34.70

Paul Choi at Goldman Sachs maintains a Buy rating and $50 price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) shares as of July 18.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biotechnology company working on medicines for genetic diseases. It is based in Palo Alto, California.

Our hedge fund data for the first quarter shows 44 hedge funds long BridgeBio Pharma, Inc. (NASDAQ:BBIO). Their total stake value was $861 million.

Follow Bridgebio Pharma Inc. (NASDAQ:BBIO)

3. Natera, Inc. (NASDAQ:NTRA)

Number of Hedge Fund Holders: 47

Share Price as of July 21: $48.42

At the end of the first quarter, 47 hedge funds held stakes in Natera, Inc. (NASDAQ:NTRA), with a total stake value of $1.4 billion.

Natera, Inc. (NASDAQ:NTRA) is another biotech company on our list. It develops and commercializes molecular testing services internationally.

A Buy rating was maintained on Natera, Inc. (NASDAQ:NTRA) shares on July 21 by Matthew Sykes at Goldman Sachs, alongside a $60 price target.

Fred Alger Management made the following comment about Natera, Inc. (NASDAQ:NTRA) in its first-quarter 2023 investor letter:

“Natera, Inc. (NASDAQ:NTRA) is a specialty lab providing genetic testing services in the reproductive health, oncology and transplant markets. Natera’s test portfolio falls under three categories: (1) reproductive health; (2) oncology; and (3) transplant. Reproductive health tests are run to screen for common genetic disorders such as trisomy 13, 18, and 21 in pregnant women – these tests are also known as non-invasive prenatal testing (NIPT). The company’s oncology franchise is led by Signatera, a test used to detect minimal residual disease (MRD) – the applications of this test are primarily to monitor therapy response and detect cancer recurrence. Lastly, Natera’s transplant franchise is led by Prospera, a test used to monitor transplant organ rejection. Natera’s tests are all based on the company’s proprietary liquid biopsy platform to detect cell-free DNA. During the period, shares contributed to performance primarily driven by strong fiscal fourth quarter results, solid 2023 financial guidance and positive reimbursement coverage decisions. Specifically on reimbursement, Natera announced in February that Centers for Medicare & Medicaid Services (CMS) would be covering the company’s Signatera Breast test for eligible breast cancer patients. This is an important update as the company is already running a significant volume of Signatera Breast tests with limited reimbursement. Consequently, we believe CMS coverage should contribute to additional revenue, margin, and cash flow. Natera also announced the first two positive commercial payer coverage decisions for Signatera in March 2023.”

Follow Natera Inc. (NASDAQ:NTRA)

2. Baxter International Inc. (NYSE:BAX)

Number of Hedge Fund Holders: 55

Share Price as of July 21: $48.85

Baxter International Inc. (NYSE:BAX) was seen in the 13F holdings of 55 funds in the first quarter, with a total stake value of $2.1 billion.

Rick Wise at Stifel holds a Buy rating and a $56 price target on Baxter International Inc. (NYSE:BAX) shares as of July 12.

Baxter International Inc. (NYSE:BAX) is a healthcare equipment company. It offers peritoneal dialysis and hemodialysis services, among more.

Here’s what Oakmark Funds said about Baxter International Inc. (NYSE:BAX) in its second-quarter 2023 investor letter:

“Baxter International Inc. (NYSE:BAX) is a provider of medical devices and health care supplies used in patient care. The company’s competitive advantages include leading scale, a large installed base and long-term customer relationships. Demand for Baxter’s products tends to be stable and predictable. We had invested in Baxter a few years ago when Joe Almeida joined the company as CEO, and we believe that he and his management team are focused on growing per share value. Recently, we got another chance to buy shares after the price fell significantly due to margin pressure from inflation, semiconductor shortages and ripple effects related to Covid-19. We see these issues as short term in nature and think that management will restore higher margins in the years ahead. As a result, we believe the stock is cheap at less than 10x our estimate of normalized earnings.”

Follow Baxter International Inc (NYSE:BAX)

1. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 73

Share Price as of July 21: $37.23

Pfizer Inc. (NYSE:PFE) is a pharmaceutical company. It sells biopharmaceutical products globally, including vaccines and other medicines.

We saw 73 hedge funds long Pfizer Inc. (NYSE:PFE) in the first quarter. Their total stake value was $2.2 billion.

Rajesh Kumar at HSBC initiated coverage on Pfizer Inc. (NYSE:PFE) shares with a Buy rating and a $50 price target on July 14.

Follow Pfizer Inc (NYSE:PFE)

See also 30 Cities With the Best Healthcare in the World and 11 Best Mid-Cap Healthcare Stocks To Buy Now.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.